Selective androgen receptor degrader (SARD) ligands and methods of use thereof
This invention provides novel indole, indazole, benzimidazole, benzotriazole, indoline, quinolone, isoquinoline, and carbazole selective androgen receptor degrader (SARD) compounds, pharmaceutical compositions and uses thereof in treating hyperproliferations of the prostate including pre-malignancies and benign prostatic hyperplasia, prostate cancer, advanced prostate cancer, castration resistant prostate cancer, other AR-expressing cancers, androgenic alopecia or other hyper androgenic dermal diseases, Kennedy's disease, amyotrophic lateral sclerosis (ALS), abdominal aortic aneurysm (AAA), and uterine fibroids, and to methods for reducing the levels (through degradation) and/or activity (through inhibition) of any androgen receptor including androgen receptor-full length (AR-FL) including pathogenic and/or resistance mutations, AR-splice variants (AR-SV), and pathogenic polyglutamine (polyQ) polymorphisms of AR in a subject.
1. A selective androgen receptor degrader (SARD) compound represented by the structure of formula XVII(1):
wherein
X 1 , X 2 , X 3 , X 4 , and X 5 are each independently N or CH, wherein if any one of X 1 , X 2 , X 3 , X 4 , and X 5 is CH, then the H is optionally replaced with R 2 , Y, or Z in the respective position, and if any one of X 1 , X 2 , X 3 , X 4 , and X 5 is not CH, then the respective position is unsubstituted; wherein at least one of X 1 , X 2 , X 3 , X 4 , or X 5 is nitrogen;
W 1 and W 2 are each independently selected from N or CH;
W 3 , W 4 , W 5 and W 6 are CH;
wherein if any one of W 1 , W 2 , W 3 , W 4 , W 5 , and W 6 is CH, then the H is optionally replaced with R 4 , Q or R 3 in the respective position, and if any one of W 1 , W 2 , W 3 , W 4 , W 5 , and W 6 is not CH, then the respective position is unsubstituted;
T is OH, OR, —NHCOCH 3 , NHCOR or
Z is NO 2 , CN, or COOH;
Y is CF 3 , F, I, Br, Cl, CN or C(R) 3 ;
R is alkyl, haloalkyl, dihaloalkyl, trihaloalkyl, CH 2 F, CHF 2 , CF 3 , CF 2 CF 3 , aryl, phenyl, F, Cl, Br, I, alkenyl or OH;
R 1 is CH 3 , CH 2 F, CHF 2 , CF 3 , CH 2 CH 3 , or CF 2 CF 3 ;
R 2 is hydrogen, halogen, CN, NO 2 , COOH, COOR, COR, NHCOR, CONHR, OH, OR, SH, SR, NH 2 , NHR, NR 2 , C 1 -C 12 -alkyl, C 1 -C 12 -haloalkyl, O—C 1 -C 12 -alkyl, O—C 1 -C 12 -haloalkyl, —SO 2 -aryl, —SO 2 -phenyl, —CO-aryl, arylalkyl, benzyl, aryl, or C 3 -C 7 -cycloalkyl;
Q is hydrogen, F, Cl, Br, I, CF 3 , CN, NO 2 , COOH, COOR, alkoxy, haloalkyl, optionally substituted linear or branched alkyl, optionally substituted linear or branched heteroalkyl, optionally substituted aryl, optionally substituted phenyl, optionally substituted cycloalkyl, optionally substituted heterocycloalkyl, optionally substituted arylalkyl, C(R) 3 , N(R) 2 , NHCOCH 3 , NHCOCF 3 , NHCOR, NHCONHR, NHCOOR, OCONHR, CONHR, NHCSCH 3 , NHCSCF 3 , NHCSR, NHSO 2 CH 3 , NHSO 2 R, OR, COR, OCOR, OSO 2 R, SO 2 R, SR, NCS, SCN, NCO or OCN;
R 3 is hydrogen, F, Cl, Br, I, CF 3 , CN, NO 2 , NH 2 , SH, COOH, COOR, alkoxy, haloalkyl, optionally substituted linear or branched alkyl, optionally substituted linear or branched heteroalkyl, optionally substituted aryl, optionally substituted phenyl, optionally substituted cycloalkyl, optionally substituted heterocycloalkyl, optionally substituted arylalkyl, C(R) 3 , N(R) 2 , NHCOCH 3 , NHCOCF 3 , NHCOR, NHCONHR, NHCOOR, OCONHR, CONHR, NHCSCH 3 , NHCSCF 3 , NHCSR, NHSO 2 CH 3 , NHSO 2 R, OR, COR, OCOR, OSO 2 R, SO 2 R, SR, NCS, SCN, NCO or OCN;
R 4 is hydrogen, F, Cl, Br, I, CF 3 , CN, NO 2 , NH 2 , SH, COOH, COOR, alkoxy, haloalkyl, optionally substituted linear or branched alkyl, optionally substituted linear or branched heteroalkyl, optionally substituted aryl, optionally substituted phenyl, optionally substituted cycloalkyl, optionally substituted heterocycloalkyl, optionally substituted arylalkyl, C(R) 3 , N(R) 2 , NHCOCH 3 , NHCOCF 3 , NHCOR, NHCONHR, NHCOOR, OCONHR, CONHR, NHCSCH 3 , NHCSCF 3 , NHCSR, NHSO 2 CH 3 , NHSO 2 R, OR, COR, OCOR, OSO 2 R, SO 2 R, SR, NCS, SCN, NCO or OCN;
n is 1, 2, or 3; and
m is 1, 2, or 3;
or its isomer, pharmaceutically acceptable salt, pharmaceutical product, polymorph, hydrate or any combination thereof.
2. The compound of claim 1 , wherein the compound is a compound of formula XVIIa(1):
3. The compound of claim 1 , wherein the compound is a compound of formula XVII(2):
4. The compound of claim 1 , wherein W 2 is N and W 1 , W 3 , W 4 , W 5 , and W 6 are CH; or W 1 is N and W 2 , W 3 , W 4 , W 5 , W 6 are CH.
5. The compound of claim 1 , wherein X 1 is N.
6. The compound of claim 1 , wherein X 2 is N.
7. The compound of claim 1 , wherein the compound is represented by the structure of formula XIX:
8. The compound of claim 1 , wherein Q is H, NO 2 , COR, alkyl, alkoxy, aryl, CN, CF 3 , F, Cl, Br or I.
9. The compound of claim 1 , wherein Z is CN.
10. The compound of claim 1 , wherein Y is Cl or CF 3 .
11. A pharmaceutical composition comprising a SARD compound according to claim 1 , or its isomer, pharmaceutically acceptable salt, pharmaceutical product, hydrate or any combination thereof, and a pharmaceutically acceptable carrier.
12. A method of treating prostate cancer (PCa) or increasing the survival of a male subject suffering from prostate cancer comprising administering to the subject a therapeutically effective amount of a compound according to claim 1 , or its isomer, pharmaceutically acceptable salt, pharmaceutical product, hydrate or any combination thereof.
13. The method according to claim 12 , wherein the prostate cancer is at least one of advanced prostate cancer, refractory prostate cancer, castration resistant prostate cancer (CRPC), metastatic CRPC (mCRPC), non-metastatic CRPC (nmCRPC), or high-risk nmCRPC.
14. The method according to claim 12 further comprising administering androgen deprivation therapy (ADT).
15. The method according to claim 12 , wherein the prostate cancer is resistant to treatment with an androgen receptor antagonist(s).
16. The method according to claim 15 , wherein the androgen receptor antagonist is at least one of enzalutamide, apalutamide, bicalutamide, abiraterone, ODM-201, EPI-001, EPI-506, AZD-3514, galeterone, AS C-J9, flutamide, hydroxyflutamide, nilutamide, cyproterone acetate, ketoconazole, or spironolactone.
17. A method of treating enzalutamide resistant prostate cancer, apalutamide resistant prostate cancer, abiraterone resistant prostate cancer, or triple negative breast cancer in a subject comprising administering to the subject a therapeutically effective amount of a compound according to claim 1 , or its isomer, pharmaceutically acceptable salt, pharmaceutical product, hydrate or any combination thereof.
18. The compound of claim 1 , wherein the compound is represented by compound 47:
19. The compound of claim 1 , wherein the compound is represented by compound 99:
20. The compound of claim 1 , wherein the compound is represented by compound 96:
21. The compound of claim 1 , wherein the compound is represented by compound 38: